Infarmed Switches On a Public Online Tracker for Medication Funding — Citizens Can Now Search SNS-Reimbursed Therapeutic Indications by INN, Brand or Indication Through the Infomed Repository

From Wednesday, 29 April, the Infarmed website carries a piece of digital-public-services plumbing that has been on patient-association wish-lists for the better part of a decade: a public, searchable record of which medications and therapeutic indications are funded by the Serviço Nacional de Saúde and on what terms. The data has technically been available for years inside the agency's evaluation reports, but it sat in PDF documents that were difficult to query and almost impossible to compare across products. The new layer integrates the funding-decision metadata directly into Infomed — the national database of medicines for human use — so any citizen can search by international nonproprietary name, brand name or therapeutic indication and see the public-funding status alongside the standard medicines information.

The change is procedural rather than substantive — no new medicines are being added to the SNS comparticipação list as a result — but the transparency effect is meaningful. Until now, an SNS user trying to find out whether a specific drug for diabetes, oncology or rheumatoid arthritis was reimbursed had to either ask the prescribing doctor, call a pharmacy, or wade through a sequence of Infarmed and ACSS publications. Pharmacists, who already operate a parallel professional database, are not the audience for this release. The audience is patients, family carers, and the patient-association layer that translates medical decisions into language people use at the kitchen table.

Why this matters for the funding debate

The reimbursement decisions Infarmed produces are increasingly the focal point of Portuguese health-policy disagreement. The standard pattern over the last five years has been: a new high-cost specialty medicine receives a positive evaluation by the European Medicines Agency, the manufacturer files for SNS reimbursement, Infarmed runs the cost-effectiveness analysis, and a decision lands months or years later — often partial, often negotiated, and often invisible to the patient looking for clarity. By making the outcome state machine-readable inside Infomed, Infarmed reduces the asymmetry between the institutional players (manufacturers, hospitals, ARS regional administrations, pharmacies) and the people who actually take the medicines.

The publication today is also a measurable input into the EU's broader push, under the Health Technology Assessment Regulation that took full effect in January 2025, to make funding-decision processes legible across member states. Portuguese decisions that previously sat in standalone PDFs can now be cited and compared with French, German or Dutch decisions — a feature the European Commission and patient-advocacy networks have been pushing in parallel. The Associação para a Promoção do Medicamento Genérico, the patient federations and the AFP (Associação de Farmácias de Portugal) all welcomed the rollout.

What is and is not included

The new layer covers therapeutic indications with public funding, the headline funding decision, and any associated conditions (such as restricted prescribing settings, mandatory clinical-criteria filters or hospital-only dispensing). It does not include the full pricing negotiation history with the manufacturer, the parallel decisions made under the medicamentos de dispensa hospitalar circuit, or the granular evaluation reasoning — which remains in the standalone evaluation reports for any user willing to dig further. The agency has signalled that further integration is on the roadmap, including a longitudinal view of when each indication was added or modified, which would let researchers reconstruct the actual policy trajectory rather than the snapshot.